IRIS
LO COCO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 134.860
AS - Asia 11.566
EU - Europa 9.877
SA - Sud America 1.667
Continente sconosciuto - Info sul continente non disponibili 1.195
AF - Africa 154
OC - Oceania 37
Totale 159.356
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 134.351
SG - Singapore 4.827
CN - Cina 2.266
UA - Ucraina 1.583
HK - Hong Kong 1.564
DE - Germania 1.340
BR - Brasile 1.332
RU - Federazione Russa 1.310
IT - Italia 1.134
IE - Irlanda 1.086
VN - Vietnam 956
FR - Francia 876
PL - Polonia 826
KR - Corea 711
GB - Regno Unito 548
FI - Finlandia 447
SE - Svezia 329
BD - Bangladesh 312
JP - Giappone 241
CA - Canada 194
IN - India 154
MX - Messico 89
AR - Argentina 81
NL - Olanda 79
IQ - Iraq 70
CO - Colombia 62
AT - Austria 60
ID - Indonesia 57
EC - Ecuador 56
VE - Venezuela 56
TR - Turchia 55
ES - Italia 51
JM - Giamaica 49
ZA - Sudafrica 43
PK - Pakistan 40
PH - Filippine 37
BE - Belgio 36
EU - Europa 35
AU - Australia 34
CR - Costa Rica 34
IR - Iran 34
CL - Cile 32
MY - Malesia 30
HN - Honduras 29
SA - Arabia Saudita 27
GT - Guatemala 25
TH - Thailandia 21
MA - Marocco 19
SV - El Salvador 19
EG - Egitto 18
NI - Nicaragua 18
NP - Nepal 18
AE - Emirati Arabi Uniti 17
EE - Estonia 17
PY - Paraguay 17
TN - Tunisia 16
UZ - Uzbekistan 16
UY - Uruguay 15
KE - Kenya 14
PR - Porto Rico 14
PT - Portogallo 14
SK - Slovacchia (Repubblica Slovacca) 14
CZ - Repubblica Ceca 13
GR - Grecia 12
PE - Perù 12
RO - Romania 12
AL - Albania 11
DZ - Algeria 11
LT - Lituania 11
OM - Oman 11
NO - Norvegia 10
SN - Senegal 10
A2 - ???statistics.table.value.countryCode.A2??? 9
CH - Svizzera 9
DO - Repubblica Dominicana 9
HU - Ungheria 9
IL - Israele 9
JO - Giordania 9
KZ - Kazakistan 9
AZ - Azerbaigian 8
DK - Danimarca 8
LB - Libano 8
TW - Taiwan 8
BB - Barbados 7
CY - Cipro 7
KG - Kirghizistan 7
RS - Serbia 7
TT - Trinidad e Tobago 7
BG - Bulgaria 5
ET - Etiopia 5
LK - Sri Lanka 5
NG - Nigeria 5
SY - Repubblica araba siriana 5
AM - Armenia 4
BA - Bosnia-Erzegovina 4
LA - Repubblica Popolare Democratica del Laos 4
PA - Panama 4
BH - Bahrain 3
BO - Bolivia 3
BY - Bielorussia 3
Totale 158.148
Salva come PNG Salva come JPEG
Città #
Woodbridge 40.477
Wilmington 33.250
Houston 30.702
Fairfield 3.703
Ann Arbor 3.125
Singapore 2.853
Ashburn 2.791
Chandler 2.033
Seattle 1.565
San Jose 1.561
Hong Kong 1.542
Cambridge 1.312
Jacksonville 1.172
Dublin 1.055
Dearborn 1.008
Medford 823
Beijing 784
Kraków 771
Santa Clara 519
Council Bluffs 508
New York 456
Lawrence 386
Dallas 344
The Dalles 319
Lauterbourg 284
Los Angeles 277
Rome 275
Moscow 273
Ho Chi Minh City 267
Hanoi 247
Tokyo 202
San Diego 181
Buffalo 155
Milan 136
São Paulo 134
Zhengzhou 110
Hangzhou 103
North Bergen 100
Mülheim 95
London 92
Helsinki 89
Norwalk 86
Columbus 83
Chicago 81
Menlo Park 81
Hefei 71
Boardman 65
Nuremberg 64
Mountain View 62
Redwood City 62
Guangzhou 61
Verona 61
Denver 59
Brooklyn 56
Redondo Beach 55
Shanghai 54
Atlanta 53
Toronto 50
Rio de Janeiro 46
Da Nang 45
Nanjing 45
Haiphong 44
San Francisco 44
Frankfurt am Main 40
Kunming 39
Orem 39
Munich 38
Phoenix 38
Warsaw 37
Montreal 36
Philadelphia 36
Jakarta 32
Brussels 31
Creede 31
Baghdad 30
Kingston 30
Belo Horizonte 25
Bologna 25
Falls Church 25
Fuzhou 25
Mumbai 25
Quito 25
Washington 25
Chennai 24
Curitiba 24
Brasília 23
Stockholm 23
Jinan 22
San Mateo 22
Chengdu 21
Johannesburg 21
Kuala Lumpur 21
Amsterdam 20
Guatemala City 20
Nanchang 20
Seoul 20
University Park 20
Hounslow 19
Indiana 19
Las Vegas 19
Totale 138.397
Salva come PNG Salva come JPEG
Nome #
Immunophenotyping of acute myeloid leukaemia: relevance of analysing different lineage-associated markers 834
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia 660
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel 584
BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib. 573
Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells 547
Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer 546
Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia 536
A case of SRSF2 mutation in chronic lymphocytic leukemia 531
A systems medicine clinical platform for understanding and managing non- communicable diseases 530
An allele-specific RT-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia 517
Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia 514
A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias 509
Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission 509
Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: Final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up 508
Identification of a potential topoisomerase II “hotspot” DNA region in the DEK gene in two t(6;9)-positive therapy-related myeloid neoplasms 500
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet 499
Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation 498
What is the standard regimen for patients with acute promyelocytic leukemia? 498
Infectious complications in patients with acute promyelocytic leukaemia treated with the AIDA regimen 496
A miRNA signature in human cord blood stem and progenitor cells as potential biomarker of specific acute myeloid leukemia subtypes 493
"Composite" lymphoma, lymphoplasmacytoid and diffuse large B-cell lymphoma of the spleen: molecular-genetic evidence of a common clonal origin 490
Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells 490
MiR-21 is overexpressed in NPM1-mutant acute myeloid leukemias 490
Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy. 485
M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis 484
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. 484
Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups 484
Acute promyelocytic leukemia: clinical and morphologic features and prognostic factors 484
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: Retrospective analysis of 530 patients 484
Utilization of molecular phenotypes to detect relapse and optimize the management of acute promyelocytic leukemia 483
A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes. 482
Development of a High-Resolution Melting Curve Analysis Screening Test for SRSF2 Splicing Factor Gene Mutations in Myelodysplastic Syndromes 481
Differential hypoxic regulation of the microRNA-146a/CXCR4 pathway in normal and leukemic monocytic cells: Impact on response to chemotherapy 481
Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts 481
Cytotoxic effects of high concentrations of sodium ascorbate on human myeloid cell lines 480
A systems medicine clinical platform for understanding and managing non- communicable diseases 479
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide 479
Treatment of elderly patients (>= 60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols 478
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies 477
Absence of HHV-8 DNA sequences in malignant mesothelioma 477
Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes 476
Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. 476
Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy 476
8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes 473
PML nuclear body disruption impairs DNA double-strand break sensing and repair in APL 473
Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients with Arsenic Trioxide and Retinoic Acid in the United States 473
Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin 471
Current management of newly diagnosed acute promyelocytic leukemia 471
Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation 470
Clonal evolution in therapy-related neoplasms 470
PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy 470
NPM1 gene deletions in myelodysplastic syndromes with 5q- and complex karyotype. 469
Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients 469
Rapid detection of IDH2 (R140Q and R172K) mutations in acute myeloid leukemia 468
PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity 468
Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. 467
Acute myeloid leukemia developing in patients with autoimmune diseases. 467
GIMEMA-AIEOP AIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children 467
Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet 467
MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis 466
Imatinib-mesylate for all patients with hypereosinophilic syndrome? 466
Idiopathic hypereosinophilic syndrome: A case evolving in B-lymphoblastic lymphoma 466
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. 463
Primary effusion lymphoma in HIV-infected patients with multicentric Castleman's disease 463
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy 462
Clustering of genomic breakpoints at the MLL locus in therapy-related acute leukemia with t(4;11)(q21;q23) 462
Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias 458
BCL-6 and the molecular pathogenesis of B-cell lymphoma 458
Multigenetic lesions in infant acute leukaemias: correlations with ALL-1 gene status 458
Podocalyxin is expressed in normal and leukemic monocytes 457
Randomized Phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: Health-related quality-of-life outcomes 456
High Δnp73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia 456
Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with ATRA and chemotherapy 455
A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms 455
Panobinostat for the treatment of acute myelogenous leukemia 454
Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients 453
The hidden genomic landscape of acute myeloid leukemia: Subclonal structure revealed by undetected mutations 453
Arsenic trioxide: its use in the treatment of acute promyelocytic leukemia 452
Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells. 451
Characteristics and clinical correlates of MPL 515W > L/K mutation in essential thrombocythemia 449
NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia 449
Rapid detection of nucleophosmin (NPM1) mutations in acute myeloid leukemia by denaturing HPLC 449
Haemolytic uremic syndrome during induction therapy in an acute promyelocytic leukemia patient with aberrant phenotype: a possible manifestation of retinoic acid syndrome [10] 448
Molecular characterization of Ph' + hybrid acute leukemia 448
High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro 448
In vitro all-trans retinoic acid sensitivity of acute myeloid leukemia blasts with NUP98/RARG fusion gene 448
Overexpression of BP1, a homeobox gene, is associated with resistance to all-trans retinoic acid in acute promyelocytic leukemia cells 446
Current treatment of acute promyelocytic leukemia. 446
Rearrangements of the BCL-6 gene in acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma: association with diffuse large-cell subtype 446
Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): a comparison with NPMc+ AML 445
Pregnancy in acute promyelocytic leukaemia after front-line therapy with arsenic trioxide and all-trans retinoic acid 444
Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia 444
Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia 444
CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy 443
Human herpes virus-8 associated primary effusion lymphoma of the pleural cavity in HIV-negative elderly men 443
Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression 442
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia 442
Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo 442
Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem 442
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia 441
Totale 47.989
Salva come PNG Salva come JPEG
Categoria #
all - tutte 342.838
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 342.838
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.872 0 0 0 163 94 232 222 185 210 286 404 1.076
2022/20235.059 580 256 188 622 452 1.222 445 357 545 39 246 107
2023/20241.512 230 76 118 35 181 368 33 112 17 32 14 296
2024/20257.317 286 1.980 889 382 80 246 760 411 837 492 491 463
2025/202611.733 906 841 1.597 695 725 351 1.824 1.364 1.645 929 402 454
2026/20275.225 490 614 2.530 1.591 0 0 0 0 0 0 0 0
Totale 159.356